Legend Strategy Deepens Biotech Push With Detailed Disclosure on Beisheng Acquisition

Legend Strategy International Holdings Group Co., Ltd. ( (HK:1355) ) has provided an update.

Legend Strategy International Holdings Group has issued a supplemental announcement regarding its acquisition of shares in Auro Hong Kong Limited, providing further detail on the business model of Beisheng Biotechnology Group associated with the deal. The disclosure underscores how the acquisition ties the company more closely to advanced bio-manufacturing infrastructure, potentially strengthening its strategic position in high-value biotechnology services.

Beisheng Biotechnology focuses on delivering higher-quality, more convenient, and lower-cost infrastructure services for DNA and strain manufacturing and related data production. Its model centers on sales and subscriptions of its Tosycon design software, manufacturing and sales of vectors and target organisms, and consulting and solutions based on its self-developed ArchiCel bio-manufacturing standard.

Beisheng’s integrated platform links design software directly with manufacturing, avoiding the fragmented procurement process typical of traditional biotech infrastructure providers and saving users significant time and sourcing effort. The company’s turnkey, self-developed industrial-grade manufacturing systems, vectors, and target organisms are designed to reduce production costs and improve efficiency for clients.

By standardizing bio-manufacturing through ArchiCel, Beisheng optimizes the interface between design and production, cutting the workload of senior R&D staff and allowing them to focus on higher-value design tasks. This also lowers the skills barrier for R&D roles, as personnel no longer need deep manufacturing expertise, potentially broadening the talent pool and improving project throughput for Beisheng’s customers.

The most recent analyst rating on (HK:1355) stock is a Hold with a HK$0.13 price target. To see the full list of analyst forecasts on Legend Strategy International Holdings Group Co., Ltd. stock, see the HK:1355 Stock Forecast page.

More about Legend Strategy International Holdings Group Co., Ltd.

Legend Strategy International Holdings Group Company Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the broader biotechnology and life-sciences services space through strategic investments. The group is expanding its presence in bio-manufacturing infrastructure and related technology solutions via acquisitions such as its stake in Auro Hong Kong Limited, which is linked to Beisheng Biotechnology’s platform-oriented business.

Average Trading Volume: 455,974

Technical Sentiment Signal: Buy

Current Market Cap: HK$198M

Find detailed analytics on 1355 stock on TipRanks’ Stock Analysis page.